Adrenal News

Looking to the future will be a key theme at the American Association of Clinical Endocrinology 2024 annual meeting with a keynote lecture focused on AI and sessions examining guidance updates and new technology.

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label portion of the GRACE phase 3 trial.

Adults with mild autonomous cortisol secretion are more likely to have advanced chronic kidney disease at adrenal adenoma diagnosis than adults with a nonfunctioning adrenal adenoma, according to study data.

Adults who achieved remission after surgery for Cushing’s disease are more likely to develop autoimmune disease than those with nonfunctioning pituitary adenomas, according to data published in Annals of Internal Medicine.

The FDA granted breakthrough therapy designation for an oral non-glucocorticoid medication for the treatment of congenital adrenal hyperplasia, according to an industry press release.

Adults with congenital adrenal hyperplasia receiving an oral corticotropin-releasing factor type 1 receptor antagonist had a greater reduction in daily glucocorticoid dose at 24 weeks than placebo, according to top-line phase 3 trial data.

Adults with endogenous Cushing’s syndrome reported that the condition moderately affects their quality of life and causes them to have symptoms about 16 days in a given month, according to findings published in Pituitary.

Nearly one-third of women with endogenous Cushing’s syndrome and normal bone mineral density have a low trabecular bone score, according to study data.

Most adults with Cushing’s disease who received ketoconazole after transsphenoidal surgery had a reduction in cortisol to normal levels, according to findings published in Frontiers in Endocrinology.

CHICAGO—In this video exclusive, Maria Fleseriu, MD, FACE, and Adina Turcu, MD, MS, talk about research on adrenal disorders presented at ENDO 2023, including artificial intelligence and a debate about which patients to screen for primary aldosteronism.